• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Molecular Templates Inc.

    9/27/24 4:01:53 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTEM alert in real time by email
    8-K
    NASDAQ false 0001183765 0001183765 2024-09-27 2024-09-27

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): September 27, 2024

     

     

    Molecular Templates, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-32979   94-3409596
    (State or other jurisdiction of
    incorporation or organization)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification No.)

     

    9301 Amberglen Blvd, Suite 100
    Austin, Texas 78729
    (Address of Principal Executive Offices) (Zip Code)

    Registrant’s telephone number, including area code: (512) 869-1555

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $0.001 par value per share   MTEM   The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    On September 27, 2024, Molecular Templates, Inc. (the “Company”) held its 2024 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, a quorum of 4,676,739 shares of the Company’s common stock, or 71.03% of the outstanding shares of common stock entitled to vote as of the record date of August 1, 2024, were present in person or represented by proxy. At the Annual Meeting, the stockholders: (1) elected Corsee Sanders, Ph.D. to the Company’s Board of Directors as a Class II director for a term of three years to serve until the 2027 annual meeting of stockholders and until her successor is elected and qualified or until her earlier death, resignation or removal (“Election of Director”); (2) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 (“Auditor Ratification”); and (3) approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement for the meeting (“Advisory Vote on Executive Compensation”). A more complete description of each of these matters is set forth in the Company’s proxy statement.

    The number of votes cast in favor or against by the stockholders and the number of abstentions and the number of broker non-votes on each of the foregoing matters are set forth below.

     

    1.

    Election of Director

     

    Nominee  

    Shares

    Voted For

     

    Shares

    Voted

    Against

     

    Shares

    Abstaining

     

    Broker

    Non-votes

    Corsee Sanders, Ph.D.

      3,031,323   553,546   139   1,091,731

     

    2.

    Auditor Ratification

     

    Shares

    Voted For

     

    Shares

    Voted

    Against

     

    Shares

    Abstaining

    4,639,921

     

    28,744

     

    8,074

     

    3.

    Advisory Vote on Executive Compensation

     

    Shares

    Voted For

     

    Shares

    Voted

    Against

     

    Shares

    Abstaining

     

    Broker

    Non-votes

    3,561,675

      22,865   468   1,091,731

     

    2


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Molecular Templates, Inc.
    Dated: September 27, 2024      
        By:  

    /s/ Eric E. Poma, Ph.D.

          Name: Eric E. Poma, Ph.D.
          Title: Chief Executive Officer

     

    3

    Get the next $MTEM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTEM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Biotech Target N V sold $845,833 worth of shares (1,279,820 units at $0.66), closing all direct ownership in the company (SEC Form 4)

    4 - Molecular Templates, Inc. (0001183765) (Issuer)

    11/18/24 9:12:24 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lalande Kevin M.

    4 - Molecular Templates, Inc. (0001183765) (Issuer)

    9/30/24 5:41:36 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Gruia Gabriela

    4 - Molecular Templates, Inc. (0001183765) (Issuer)

    9/30/24 5:37:40 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTEM
    SEC Filings

    View All

    SEC Form 8-K filed by Molecular Templates Inc.

    8-K - Molecular Templates, Inc. (0001183765) (Filer)

    1/2/25 4:13:52 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Molecular Templates Inc.

    8-K - Molecular Templates, Inc. (0001183765) (Filer)

    12/19/24 4:11:29 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Molecular Templates Inc.

    DEFA14A - Molecular Templates, Inc. (0001183765) (Filer)

    12/4/24 4:10:56 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTEM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

    Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

    5/14/25 4:30:00 PM ET
    $CLDI
    $MTEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

    SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

    4/23/25 8:00:00 AM ET
    $CLDI
    $MTEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules

    AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or the "Company")), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, was notified on December 16, 2024 by the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") of the Staff's determination pursuant to Nasdaq Listing Rule 5101 that the Company is a "public shell," and that, in the view of the Staff, the continued listing of the

    12/19/24 4:10:00 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Biotech Target N V bought $587,500 worth of shares (250,000 units at $2.35), increasing direct ownership by 24% to 1,279,820 units (SEC Form 4)

    4 - Molecular Templates, Inc. (0001183765) (Issuer)

    4/4/24 8:13:35 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Molecular Templates with a new price target

    BofA Securities initiated coverage of Molecular Templates with a rating of Buy and set a new price target of $12.00

    4/21/21 6:52:47 AM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Molecular Templates with a new price target

    UBS initiated coverage of Molecular Templates with a rating of Neutral and set a new price target of $13.00

    2/1/21 7:51:02 AM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTEM
    Leadership Updates

    Live Leadership Updates

    View All

    Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

    Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

    5/14/25 4:30:00 PM ET
    $CLDI
    $MTEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

    SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

    4/23/25 8:00:00 AM ET
    $CLDI
    $MTEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

    AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appointment of Dr. Maurizio Voi to the role of Chief Medical Officer. Dr. Voi possesses more than 35 years of wide-ranging drug development experience. Dr. Voi will begin his new role on October 2, 2023. Dr. Voi joins MTEM from Novartis, where he served as Vice President, Global Program Head, for the PD-1 antibody Tislelizumab since April 2021. He was previously Global Program Head, Melanoma, at Novartis, a pos

    9/28/23 4:11:00 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

    SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

    11/18/24 9:49:56 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

    SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

    11/14/24 4:37:56 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

    SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

    11/12/24 9:31:46 AM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care